KLOW Blend Research Peptide

GLOW contains BPC-157, TB-500, and GHK-Cu, focusing on angiogenesis, cell migration, and collagen synthesis. KLOW adds KPV, which brings powerful NF-κB inhibition and anti-inflammatory activity. This fourth component is particularly relevant for inflammatory conditions and extends the blend's research applications to include gut inflammation and inflammatory skin conditions.

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). Unlike full-length α-MSH which works through melanocortin receptors, KPV is transported into cells via PepT1 transporters. Once inside cells, it inhibits NF-κB activation and reduces pro-inflammatory cytokine production. Importantly, PepT1 expression is upregulated during inflammatory bowel disease, making KPV particularly effective in inflamed gut tissue.

KPV's anti-inflammatory effects are NOT melanocortin receptor-mediated. Instead, KPV enters cells through the PepT1 di/tripeptide transporter, which is normally expressed in the small intestine and induced in the colon during IBD. This allows KPV to directly access intracellular inflammatory pathways at nanomolar concentrations, inhibiting NF-κB activation and reducing the duration of inflammatory signaling.

KPV has been studied in models of inflammatory bowel disease (DSS- and TNBS-induced colitis), contact dermatitis, cutaneous vasculitis, asthma, rheumatoid arthritis, and ocular inflammation. Research shows that oral KPV significantly reduces inflammation, body weight loss, and tissue damage in colitis models. Studies in Gastroenterology (2007) demonstrated that KPV's anti-inflammatory effect works through PepT1-mediated uptake and subsequent NF-κB/MAPK pathway inhibition.

No. All four peptides are research compounds. BPC-157 and TB-500 are investigational peptides with no FDA approval and are banned by WADA. GHK-Cu is used in cosmetic formulations but is not approved as a therapeutic. KPV is a naturally occurring peptide fragment used for research purposes. KLOW is intended for laboratory and preclinical research applications only.

Yes, research indicates KPV is effective via oral administration. Because KPV is transported by PepT1 (a di/tripeptide transporter expressed in the intestine), it can be absorbed intact from the gut. Studies in Gastroenterology showed that oral KPV reduced inflammation in colitis models. The other three components (BPC-157, TB-500, GHK-Cu) are typically administered via injection in research protocols.

Lyophilized (powder) form should be stored at -20°C for long-term stability. Once reconstituted, store at 2-8°C (refrigerated) and use within 7 days. Protect from light and avoid repeated freeze-thaw cycles. Each component has slightly different stability profiles, so follow manufacturer guidelines for specific formulations.

No. All products are supplied strictly for laboratory research use only. They are not approved for
human or veterinary use and are not intended for diagnostic or therapeutic applications.